A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active:	No
Cancer Type:	Head and Neck Cancer Neuroendocrine Tumor Thyroid Cancer Unknown Primary	NCT ID:	NCT04211337
Trial Phases:	Phase III	Protocol IDs:	17478 (primary) J2G-MC-JZJB 2019-001978-28 NCI-2020-00277
Eligibility:	12 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Loxo Oncology, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04211337

Summary

The reason for this study is to see if the study drug selpercatinib is safe and more
effective compared to a standard treatment in participants with rearranged during
transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or
has spread to other parts of the body. Participants who are assigned to the standard
treatment and discontinue due to progressive disease have the option to potentially crossover
to selpercatinib.

Objectives

Adaptive sample size re-estimation will be performed at interim analysis. The sample size
could be increased from approximately 250 to 400 depending on the results of interim
analysis.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.